Gary John Tresadern

This inventor holds 19 USPTO granted patents and 5 published patent applications, plus 9 CIPO patents and 15 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Janssen Pharmaceutica Nv, Janssen Pharmaceuticals, Inc., Addex Pharma, S.a.. Active years: 2013-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gary John Tresadern. Retrieved from https://idiyas.com/inventor/gary-john-tresadern

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 5)

% Patents Active = 31.6

CIPO Patents = 9 (Patent Applications = 6)

EPO Patents = 15 (Patent Applications = 21)

Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 70(Granted Patents)

Company Filing History:

10 out of 2,101

Janssen Pharmaceutica Nv

patents

9 out of 161

Janssen Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2013-2022

Loading Chart...

Areas of Expertise:

PDE2 Inhibitors

Beta-Secretase Inhibitors

Allosteric Modulators

Triazolo Compounds

Neurological Disorders

Psychiatric Disorders

Bicyclic Thiazoles

Imidazo Derivatives

mGluR2 Receptors

mGluR5 Receptors

Pyrazolo Compounds

Gamma Secretase Modulators

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11319321 - [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors (2022-05-03),

2. 11053248 - [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors (2021-07-06),

3. 10947242 - [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors (2021-03-16),

4. 10519162 - 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors (2019-12-31),

5. 10071095 - 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders (2018-09-11),

6. 10005785 - Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors (2018-06-26),

7. 9840507 - 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) (2017-12-12),

8. 9828350 - 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) (2017-11-28),

9. 9737533 - 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders (2017-08-22),

10. 9271967 - 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors (2016-03-01),

11. 9226930 - 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders (2016-01-05),

12. 9174953 - Bicyclic thiazoles as allosteric modulators of mGluR5 receptors (2015-11-03),

13. 9040707 - Bicyclic thiazoles as allosteric modulators of mGluR5 receptors (2015-05-26),

14. 9012448 - 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors (2015-04-21),

15. 8993591 - 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors (2015-03-31),

Title: Gary John Tresadern: Innovator in Pharmaceutical Chemistry

Introduction

Gary John Tresadern is a distinguished inventor based in Toledo, ES, known for his significant contributions to the field of pharmaceutical chemistry. With an impressive portfolio of 19 patents, he has made strides in the development of innovative compounds that have potential therapeutic applications.

Latest Patents

Tresadern's latest patents focus on novel [1,2,4]triazolo[1,5-a]pyrimidine compounds functioning as inhibitors of phosphodiesterase 2 (PDE2). His invention encompasses unique [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives, which are not only pivotal for the pharmaceutical industry but are also aimed at treating various neurological and psychiatric disorders. The patents detail pharmaceutical compositions that include these compounds, the processes for their preparation, and their potential uses in medical treatments involving PDE2.

Career Highlights

Throughout his career, Gary has collaborated with prominent pharmaceutical companies, including Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. His experience at these organizations has likely influenced his innovative approaches in drug development and research methodologies.

Collaborations

Gary John Tresadern has had the privilege of working alongside notable colleagues, such as Andrés Avelino Trabanco-Suárez and Gregor James MacDonald. These collaborations have perhaps enriched his research endeavors and enhanced the impact of his inventions within the pharmaceutical field.

Conclusion

Overall, Gary John Tresadern stands out as a notable inventor whose innovative work in the realm of pharmaceutical chemistry contributes to advancing therapeutic solutions. His patents reflect a commitment to addressing critical healthcare challenges, marking him as an influential figure in the ongoing quest for new treatments.

Profile summary based on public USPTO records.